IgAN,iganephropathy,kidney,nephrology,nephtwitter,NKFClinicals

Mashup Score: 0

Baseline Characteristics in VISIONARY Trial of Sibeprenlimab | Docwire News - 4 day(s) ago

At SCM25, researchers presented baseline characteristics of patients in the phase 3 VISIONARY trial of sibeprenlimab for IgA nephropathy (IgAN).

Source: www.docwirenews.com

Categories: General Medicine News, Partners & KOLs

Tweet Tweets with this article
- Neph_Times
  
  VISIONARY is the largest phase 3 trial of an #IgAN treatment to date and is intended to evaluate the efficacy and safety of sibeprenlimab. #iganephropathy #kidney #nephrology #nephtwitter #NKFClinicals https://t.co/6xsfoJF4Zy https://t.co/j34QEGFJBR